BioSpace News Archive

The global Cardiac Biomarkers Market size is expected to hit around US$ 20.3 billion by 2030 and is projected to grow at a CAGR of 15.2% during forecast period 2021 to 2030.

The global Endoscopy Operative Devices market size is expected to hit around US$ 20.7 billion by 2030 from valued at US$ 10.0 billion in 2020 with a CAGR of 6.1% during forecast period 2021 to 2030.

MaxCyte, Inc. announced Company management will participate in the following investor conferences:

Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), today announced top-line results at 12 weeks from its Phase 2 trial for CBP-307 (CBP-307CN002), a once-daily, orally administered, selective sphingosine 1-phosphate (S1P) receptor modulator in development for the treatment of ulcerative colitis (UC).

Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) today announced that it will report its financial results for the quarter March 31, 2022 on Monday, May 9, 2022, after the close of the U.S. financial markets.

Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report first quarter 2022 financial results on Thursday, May 12, 2022.

Rani Therapeutics Holdings, Inc., a clinical stage biotherapeutics company focused on the oral delivery of biologics, announced that the company’s Chief Executive Officer, Talat Imran, will present at two upcoming investor conferences in May.

ABVC Biopharma, Inc. today announced that BioKey, a wholly-owned subsidiary of the company based in Fremont, California, has entered into a $3.0 million clinical services contract with NeuCen BioMed Co. Ltd.

Evoke Pharma, Inc. today announced that the Company is scheduled to release its first quarter 2022 financial results on Tuesday, May 10, 2022, after the market closes.

Journey Biosciences, Inc. A new study recently published in the journal Diabetes Care continues to validate the role that specific biomarkers - advanced glycation endproducts (AGEs) - in predicting if a person with diabetes will develop kidney disease.